AbstractNo abstract available
Keywords: autoimmune diseases; dermatomyositis; epidemiology; polymyositis.
Conflict of interest statement
Competing interests: ATJM has received fees from Abbvie, Actelion, CSL Behring, Experf, Novartis and Shire, and declares speaking fees from Astra-Zeneca and BMS in the last 5 years. PG is a medical expert for LFB (Laboratoire Français du Biofractionnement) and has received fees from Abbvie, Actelion, Boehringer Ingelheim France, Bouchara-Recordati, Novartis, Pfizer and Roche in the last 5 years. OL has received expert testimony and consultancy fees from BMS France, MSD, Astra Zeneca; consultancy fees from Genzyme, Incyte, and expert testimony for Janssen. Other authors declare that they have no conflicts of interest.
Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.J Med Case Rep. 2019 Jun 2;13(1):168. doi: 10.1186/s13256-019-2105-9. J Med Case Rep. 2019. PMID: 31153385 Free PMC article.
Editorial: A New Classification of Adult Autoimmune Myositis.Arthritis Rheumatol. 2017 May;69(5):878-884. doi: 10.1002/art.40063. Epub 2017 Apr 6. Arthritis Rheumatol. 2017. PMID: 28382651 No abstract available.
Immune checkpoint failures in inflammatory myopathies: An overview.Autoimmun Rev. 2018 Aug;17(8):746-754. doi: 10.1016/j.autrev.2018.01.026. Epub 2018 Jun 6. Autoimmun Rev. 2018. PMID: 29885538 Review.
Autoantibodies against a specific nuclear RNP protein in sera of patients with autoimmune rheumatic diseases associated with myositis.J Immunol. 1987 Apr 15;138(8):2463-8. J Immunol. 1987. PMID: 3494067
Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis.Presse Med. 2011 Apr;40(4 Pt 2):e209-18. doi: 10.1016/j.lpm.2010.12.013. Epub 2011 Mar 3. Presse Med. 2011. PMID: 21376512 Review.